Brooks Laboratories Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹20.21 crore, reflecting a quarter-on-quarter *(QoQ) increase of 21.97 per cent from ₹16.57 crore. This corresponds to a year-on-year *(YoY) decline of 13.34 per cent.
Operating Profit
Operating Profit stands at ₹0.68 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 8.11 per cent from ₹0.74 crore. This corresponds to a year-on-year *(YoY) growth of 154.40 per cent.
PBDT
PBDT stands at ₹1.93 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 67.23 per cent from ₹5.89 crore. This corresponds to a year-on-year *(YoY) growth of 316.85 per cent.
Profit Before Tax
Profit Before Tax stands at ₹1.52 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 72.36 per cent from ₹5.50 crore. This corresponds to a year-on-year *(YoY) growth of 218.75 per cent.
Net Profit
Net Profit stands at ₹1.52 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 72.36 per cent from ₹5.50 crore. This represents a 204.11 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Brooks Laboratories Ltd Earnings
- YOY
- QOQ
Brooks Laboratories Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Brooks Laboratories Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Brooks Laboratories Ltd Financial Reports
Brooks Laboratories Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Brooks Lab. | 1.13% | 11.49% | 32.10% | 59.81% | -14.50% | -49.98% |
| Coral Labs. | 2.15% | 30.74% | 30.90% | 71.55% | 44.67% | 10.67% |
| Achyut Healthcar | 5.48% | 22.21% | 67.48% | 80.00% | 70.74% | 171.27% |
| Nectar Lifesci. | 0.35% | 0.52% | -3.99% | 12.23% | -42.60% | -48.48% |
| Syschem (India) | 1.13% | -2.16% | -10.93% | -2.40% | -7.53% | -4.85% |
| Novelix Pharma. | 1.37% | 1.87% | 51.00% | 40.68% | 36.00% | 151.55% |
| Accretion Nutraveda | -1.12% | 3.88% | 5.12% | 36.67% | 38.60% | 38.60% |
Company Info
Company Information
Chairman : Atul Ranchal
Managing Director : Rajesh Mahajan
Director & Chief Executive Off : Durga Sankar Maity
Independent Director : Rajnish Kumar Bedi
Independent Director : Deepak Mahajan
Independent Director : Sonia Gupta
Company Secretary : Jyoti Sancheti